| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.9M | — | +183.2% |
| Cost of Revenue | $1.6M | — | +67.3% |
| R&D Expense | $18.2M | — | +144.9% |
| SG&A Expense | $28.6M | — | +183.3% |
| Operating Income | -$41.5M | — | -158.7% |
| Net Income | -$40.2M | — | -138.8% |
| EPS (Basic) | -$2.93 | — | -3.2% |
| EPS (Diluted) | -$2.93 | — | -3.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $185.5M | -10.7% | +40.8% |
| Accounts Receivable | $8.8M | +40.6% | +166.3% |
| Current Assets | $207.2M | -9.5% | +38.5% |
| Total Assets | $257.9M | -6.9% | +33.7% |
| Current Liabilities | $29.6M | -3.9% | +144.1% |
| Total Liabilities | $30.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$42.3M | — | -155.3% |
| Capital Expenditures | $1.7M | — | — |
| Investing Cash Flow | -$1.7M | — | — |
| Financing Cash Flow | $20.2M | — | -59.2% |
| Free Cash Flow | -$44.0M | — | -165.4% |
| +146.7% |
| Stockholders' Equity | $227.1M | -7.3% | +25.9% |